Latest News
See all →
ITM to Provide COMPETE Trial Insights at SNMMI 2025 Annual Meeting in Oral Presentation and Satellite Symposium
Garching / Munich, Germany, June 13, 2025 -ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced…
Read more
ITM Secures Up to $262.5m in Non-dilutive Debt Financing with Blue Owl Managed Funds
- Debt capital to support commercial readiness and potential U.S. launch of n.c.a.177Lu-edotreotide (ITM-11), following positive Phase 3 results
- Flexible…
ITM and Radiopharm Sign Supply Agreement for n.c.a. Lutetium-177
Garching / Munich, Germany and Sydney, Australia, May 19, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech…
Read more
